Post-stroke mRNA expression profile of MMPs: effect of genetic deletion of MMP-12

Koteswara Rao Nalamolu, Bharath Chelluboina, Ian B Magruder, Diane N Fru, Adithya Mohandass, Ishwarya Venkatesh, Jeffrey D Klopfenstein, David M Pinson, Krishna M Boini, Krishna Kumar Veeravalli

ABSTRACT

Background and purpose Recent reports from our laboratory demonstrated the post-ischaemic expression profile of various matrix metalloproteinases (MMPs) in rats and the detrimental role of MMP-12 in post-stroke brain damage. We hypothesise that the post-stroke dysregulation of MMPs is similar across species and that genetic deletion of MMP-12 would not affect the post-stroke expression of other MMPs. We tested our hypothesis by determining the pre-ischaemic and post-ischaemic expression profile of MMPs in wild-type and MMP-12 knockout mice.

Methods Focal cerebral ischaemia was induced in wild-type and MMP-12 knockout mice by middle cerebral artery occlusion procedure by insertion of a monofilament suture. One hour after ischaemia, reperfusion was initiated by removing the monofilament. One day after reperfusion, ischaemic brain tissues from various groups of mice were collected, and total RNA was isolated and subjected to cDNA synthesis followed by PCR analysis.

Results Although the post-stroke expression profile of MMPs in the ischaemic brain of mice is different from rats, there is a clear species similarity in the expression of MMP-12, which was found to be predominantly upregulated in both species. Further, the post-stroke induction or inhibition of various MMPs in MMP-12 knockout mice is different from their respective expression profile in wild-type mice. Moreover, the brain mRNA expression profile of various MMPs in MMP-12 knockout mice under normal conditions is also different to their expression in wild-type mice.

Conclusions In the ischaemic brain, MMP-12 upregulates several fold higher than any other MMP. Mice derived with the genetic deletion of MMP-12 are constitutive and have altered MMP expression profile both under normal and ischaemic conditions.

INTRODUCTION

The post-stroke dysregulation of matrix metalloproteinases (MMPs) during the acute phases after ischaemia and reperfusion has been associated with increased neurovascular disruption and brain injury. Post-stroke dysregulation of MMPs leads to blood–brain barrier disruption, cerebral oedema, haemorrhage, leucocyte infiltration and inflammation. In the early stages after ischaemic stroke, MMPs participate in the injury process. However, during the later stages after stroke, MMPs contribute to recovery. MMP inhibitors have shown promise in animal models of ischaemic stroke. However, inhibition of MMPs during the recovery phase after stroke increased brain injury, suppressed neurovascular remodelling and impaired functional recovery. Therefore, the timing of the inhibition of MMPs after stroke is critical. It is the timing of MMP inhibition and also the type of MMP that is inhibited that influences the overall outcome. Upregulation of MMP-1, MMP-2, MMP-3, MMP-8, MMP-9, MMP-10 and MMP-13 was reported in human ischaemic brain tissues. Of all the MMPs, MMP-2 and MMP-9 were well reported for their role in the context of ischaemic brain damage. Recent literature highlighted both detrimental and beneficial roles of several other MMPs such as MMP-3, MMP-8, MMP-10, MMP-12 and MMP-13 in the context of ischaemic stroke.

Because of the critical role various MMPs have on injury and during the recovery process after ischaemic stroke, investigating the post-stroke expression profile of all the known MMPs and understanding their contribution to the injury/recovery process would help the researchers to discover novel strategies to treat ischaemic stroke. We recently reported in a rat model the temporal expression profile of the majority of the known MMPs at various reperfusion times subsequent to a 2-hour focal cerebral ischaemia. We hypothesise that the post-stroke dysregulation of MMPs is similar across species. In this study, we tested our hypothesis by evaluating the post-stroke expression profile of these MMPs at 1-day reperfusion in a mouse model of ischaemic stroke. We also hypothesise that the genetic deletion of any MMP, for example, MMP-12 in this study, would not affect the post-stroke expression of other MMPs. We tested our hypothesis by determining the...
pre-ischaemic and post-ischaemic expression profile of MMPs in wild-type as well as MMP-12 knockout mice. Our results indicated a predominant upregulation of MMP-12 in the ischaemic brain of mice. The degree of post-stroke induction of MMP-12 as compared with other MMPs in mice is in agreement with our recent findings in rats. The post-stroke expression of other MMPs except MMP-9 is different in mice and rats. Further, the genetic deletion of MMP-12 altered both the pre-ischaemic and post-ischaemic expression of MMPs compared with wild-type mice.

METHODS
Ethics statement
The Institutional Animal Care and Use Committee (IACUC) of the University of Illinois College of Medicine at Peoria approved the study design, surgical manipulations, postoperative care and humane endpoints. All the procedures performed on animals complied with the approved IACUC protocol.

Animals and experimental design
Healthy, young male MMP-12 knockout (strain: B6.129X-Mmp12<tm1Sds>/J) and respective wild-type (strain: C57BL/6J) mice procured from the Jackson Laboratory (USA) were used in this study. Animals were housed in a 12-hour light/dark cycle with a controlled temperature and humidity and free access to food and water. All animal experiments were conducted in accordance with the Guide for the Care and Use of Laboratory Animals and the approved IACUC protocol. Mice were randomised to various groups. Middle cerebral artery occlusion (MCAO) subjected wild-type and MMP-12 knockout mice were from groups 2 and 4, respectively. Sham-operated wild-type and MMP-12 knockout mice were from groups 1 and 3, respectively. All animals from the four groups were euthanised 1 day post-MCAO procedure. Because of the mortality associated with the MCAO procedure, we increased the number of animals in each group to attain the required sample size for statistical analysis. Animals that did not show post-stroke symptoms after MCAO procedure were excluded from the study.

Induction of focal cerebral ischaemia and reperfusion
After the animals reached a weight of ~23.5 g, they were subjected to right MCAO procedure by using a silicone rubber–coated monofilament suture (Doccol, California, USA). Briefly, a ventral midline incision (~15–20 mm) was made in the neck and the right common carotid, internal carotid and external carotid arteries were surgically exposed. The external carotid artery (ECA) was permanently ligated rostral with one ligature. Another loose ligature was made to the ECA near the bifurcation. Two microaneurysm clips were applied each to the common carotid artery (CCA) and internal carotid artery (ICA). A small puncture opening was made to the ECA between the two ligatures. The monofilament was inserted through the opening on ECA and advanced into ICA. The microaneurysm clip was removed from ICA, and the monofilament was gently further advanced into ICA up to 9 to 10 mm distance that is pre-marked on the monofilament. The other loose ligature was tightened around the ECA containing the monofilament. The microaneurysm clip on CCA was removed, and skin on the neck incision was closed with surgical wound clips. To restore the blood flow 1 hour after MCAO, the surgical site was reopened by removing the wound clips. The microaneurysm clip was again applied to CCA, the knot was loosened, the monofilament was withdrawn and the knot was re-tied to stop bleeding. The microaneurysm clip on CCA was removed and skin was sutured to close the neck incision.

RNA extraction, cDNA synthesis and real-time PCR analysis
From the entire ipsilateral hemisphere of mice brains, total RNA was extracted using TRIzol reagent (Invitrogen, USA), reverse transcribed to cDNA with iScript cDNA synthesis kit (Bio-Rad Laboratories, USA) and used for real-time PCR analysis by using SYBR Green method. Briefly, reaction set-up for each cDNA sample was assembled using the FastStart SYBR Green Master (Roche, Indianapolis, Indiana, USA) as per the manufacturer’s instructions. Samples were subjected to 40 cycles at 95°C for 15 s, 60°C for 1 min and 72°C for 1 min in iCycler IQ (Multi Colour Real-Time PCR Detection System; Bio-Rad Laboratories, Hercules, California, USA). Data were collected and recorded using the iCycler IQ software (Bio-Rad Laboratories) and expressed as a function of the threshold cycle (ΔCt), which represents the number of cycles at which the fluorescent intensity of the SYBR Green dye is significantly above that of the background fluorescence. The genes and their respective forward and reverse primer sequences analysed by real-time PCR are listed in table 1. β-ACTIN served as a housekeeping gene. Average of Ct values were normalised with average Ct values of β-actin. After normalisation of the Ct values, fold differences were calculated by using the formula 2^{-ΔΔCt of test} / 2^{-ΔΔCt of controls}.

RT-PCR analysis and agarose gel electrophoresis
To validate the changes in mRNA expression among groups, RT-PCR analysis was performed for certain genes such as MMP-12 and MMP-9 along with the housekeeping gene β-actin using GoTaq Green Master Mix (Promega) as per the manufacturer’s instructions. RT-PCR was set up in C1000 Touch Thermo cycler (Bio-Rad Laboratories) using the following PCR cycle: (95°C for 5 min (95°C for 30 s, 58°C–62°C for 45 s and 72°C for 45 s) × 35 cycles, and 72°C for 10 min). RT-PCR products were resolved on 2% agarose gels containing ethidium bromide, visualised and photographed under UV light.

Statistical analysis
Statistical analysis of the data was performed using GraphPad Prism software (V.3.02). Quantitated data of PCR analysis were tested for normality and equality of variances between groups. The data that were normally...
Table 1  Mouse-specific genes analysed by PCR

| Gene   | Accession number | Forward primer (5′–3′) | Reverse primer (5′–3′) |
|--------|------------------|------------------------|------------------------|
| MMP-1a | NM_032006        | ccttccttgctgttgcttc    | cttctgcattctacggtt    |
| MMP-1b | NM_032007        | gttgaaagcaagaggtgat    | gttcacaagggaggtgt    |
| MMP-2  | NM_008610        | gtcgccccctaaacagacaa   | gttctcgatgtgggtctg    |
| MMP-3  | NM_010809        | cagactgctcagtttcctcat  | gttgctgatcctacacagaga |
| MMP-7  | NM_010810        | cggagatgctcactttgaca   | cagctgttctctttctc    |
| MMP-8  | NM_008611        | gctctcccaagtacgtaaca   | acctccacatcgacgagttc |
| MMP-9  | NM_013599        | cgcctgatcctccacctact   | aacacacagggttgcccct   |
| MMP-10 | NM_019471        | acccaccactcactttccca   | gttgcaagtctgcacatttc |
| MMP-11 | NM_008606        | cccctcaggtgtgcagttgaa  | caggtcagttccccgtgtg   |
| MMP-12 | M82831           | ccaagacattcctcattctat  | gtttcaacacagtacatc    |
| MMP-13 | NM_008607        | ttatattggtctgccatgta   | ctctggttttgggtgcat    |
| MMP-14 | NM_008608        | cgcctcagtccaaagttctat  | gccacacagggggtgtata   |
| MMP-15 | NM_008609        | cccccagcctcactctttctct | ccagctactggtgccgtt    |
| MMP-16 | NM_019724        | gggagacattcctctttgata   | cccatccaggtacgccagtt  |
| MMP-17 | NM_011846        | caccctacatgacaggtgat   | ccttgtagttcgggtgcat   |
| MMP-21 | NM_152944        | gactgagccagcagacagggc   | gttgctgtggtcgggtt    |
| MMP-25 | NM_00103339      | gtcctgactgtatgtgtcacc  | ccctccacactgctcactca  |
| MMP-28 | NM_001320300     | gaggcctgaagacgctcttg    | ccagacactcagtctgaca   |
| β-actin| NM_007393.5      | agccatgtagtcagcatcctc   | ctcctagctgtgggtgtgaa  |

Table 2  Matrix metalloproteinases (MMPs) that are either upregulated or downregulated after focal cerebral ischaemia and reperfusion in rats and mice

| Gene   | Δ Fold over sham in rats | Δ Fold over sham in mice |
|--------|--------------------------|--------------------------|
| MMP-1a | No change                | −13.08                   |
| MMP-2  | No change                | 11.12                    |
| MMP-3  | 11.28                    | No change                |
| MMP-8  | No change                | 279.55                   |
| MMP-9  | 16.05                    | 24.39                    |
| MMP-10 | No change                | −247.83                  |
| MMP-12 | 47.15                    | 763.79                   |
| MMP-15 | No change                | −22.33                   |
| MMP-16 | No change                | −29.74                   |
| MMP-17 | No change                | −32.47                   |
| MMP-21 | No change                | −53.60                   |

RESULTS
Dysregulation of MMPs after ischaemic stroke is not the same in rats and mice
Our recent study demonstrated an upregulation (>10-fold vs sham) of MMP-3, MMP-9 and MMP-12 in ischaemic rat brains at 1 day reperfusion after a 2-hour focal cerebral ischaemia. Further, we noticed that the post-stroke induction of MMP-12 in rats was higher than any other MMPs tested. In contrast to the expression pattern that was previously reported in the ischaemic brain of rats, in this study, MMP-2, MMP-8, MMP-9 and MMP-12 were upregulated (>10-fold vs sham) and MMP-1a, MMP-10, MMP-15, MMP-16, MMP-17 and MMP-21 were downregulated (>10-fold vs sham) in the ischaemic brains of mice (Table 2). Of all the MMPs tested, MMP-12 upregulation (~763-fold vs sham) was predominant in mice. Post-stroke induction of MMP-8 (~279-fold vs sham) in mice was the largest after MMP-12. Interestingly, marked downregulation of MMP-10 (~247-fold vs sham) expression was noticed in mice.

Genetic deletion of MMP-12 alters the post-stroke dysregulation of MMPs
There is no difference in the post-stroke expression of MMP-12 in the ischaemic brain of MMP-12 knockout mice as compared with their sham. As expected, significant upregulation in the post-stroke expression of MMP-12 was
distributed but has unequal variances between groups. Results are expressed as the mean±SD. Differences in the values were considered significant at P <0.05.
noticed in wild-type mice (figure 1A; unpaired t-test with Welch’s correction; Welch corrected t=3.608; P=0.0154, n=6). Genetic deletion of MMP-12 did not affect the post-stroke expression of MMP-9 (figure 1A, B). As mentioned earlier, marked upregulation of MMP-8 (~279-fold vs sham) and downregulation of MMP-10 (~247-fold vs sham) were noticed in wild-type mice subjected to 1-hour ischaemia followed by 1-day reperfusion (figure 2).

Genetic deletion of MMP-12 in mice showed a significant difference as compared with wild-type mice in the post-stroke expression of several MMPs such as MMP-1α (figure 2; unpaired t-test with Welch’s correction; Welch corrected t=3.699; P=0.0140, n=6), MMP-2 (figure 2; unpaired t-test with Welch’s correction; Welch corrected t=5.062; P=0.0023, n=6), MMP-8 (figure 2; unpaired t-test with Welch’s correction; Welch corrected t=4.122; P=0.0092, n=6), MMP-10 (figure 2; unpaired t-test with Welch’s correction; Welch corrected t=3.812; P=0.0125, n=6), MMP-21 (figure 2; unpaired t-test with Welch’s correction; Welch corrected t=5.930; P=0.0019, n=6) and MMP-28 (figure 2; unpaired t-test with Welch’s correction; Welch corrected t=4.773; P=0.005, n=6). As mentioned earlier, MMP-15, MMP-16 and MMP-17 were downregulated (>10-fold vs sham) in the ischaemic brain of wild-type mice (table 2). Although the downregulation of MMP-15, MMP-16 and MMP-17 was prevented in MMP-12 knockout mice as compared with wild-type mice, the differences were not significant.

**Expression pattern of MMPs is not similar in MMP-12 knockout and wild-type mice**

As we noticed significant differences in the expression pattern of various MMPs in the ischaemic brain of wild-type and MMP-12 knockout mice that were subjected to 1-day reperfusion after 1-hour focal cerebral ischaemia, we tested the mRNA expression pattern of MMPs in these mice and under normal conditions. Our results showed that the expression of MMPs in MMP-12 knockout mice was different to their expression in wild-type mice. Except MMP-8, which showed an increased expression (~264-fold vs wild type), the expression of almost all the MMPs tested was less in MMP-12 knockout mice as compared to their expression level in wild-type mice under normal conditions (figure 3). Interestingly, the decrease in the mRNA expression of MMP-10, MMP-15, MMP-21 and MMP-28 was prominent (>50-fold vs wild type) and the decrease was more than the degree of reduction in MMP-12 mRNA expression in MMP-12 knockout mice.

**DISCUSSION**

In this study, we showed the post-stroke expression profile of various MMPs in mouse brain after focal cerebral ischaemia and reperfusion. We noticed that the induction or inhibition of MMPs in mice after ischaemic stroke was different to the expression pattern that we recently reported in rats.10 While comparing the expression pattern of MMPs in mice versus rats, we here discuss only the increasing or decreasing trend but not the degree of increase or decrease, as the induction time of ischaemia (1 hour in mice vs 2 hours in rats) in these rodent models is different. MMP-3, MMP-9 and MMP-12 were upregulated (>10-fold vs sham) and none of the MMPs tested were downregulated in rats.10 In contrast to rats, in this study, MMP-2, MMP-8, MMP-9 and MMP-12 were upregulated (>10-fold vs sham), whereas MMP-1α, MMP-10, MMP-15, MMP-16, MMP-17 and MMP-21 were downregulated (>10-fold vs sham) in mice. MMP-1, MMP-2,
MMP-3, MMP-8, MMP-9, MMP-10 and MMP-13 proteins were upregulated in the ischaemic brain tissues of deceased patients who had an ischaemic stroke within the previous 4 days. The degree of severity of ischaemia and the presence or absence of reperfusion could be the possible reasons for the observed differences in the expression of MMPs in humans and rodent species.

Despite the differences in the expression pattern of various MMPs in mice versus rats, MMP-9 was upregulated in the ischaemic brain of both these rodent species at 1-day reperfusion. Consistent with our findings, in a recent review, authors have listed the studies that showed the induction of MMP-9 in these animal models and suggested the inhibition of MMP-9 (either by chemical inhibitors, MMP-9 neutralising antibodies or MMP-9 specific siRNAs/shRNAs) as a therapeutic strategy to attenuate post-stroke brain damage. The post-stroke induction of MMP-9 was also reported in non-human primates and in human brain. It was shown in different ischaemic models that the genetic deletion of MMP-9 in mice attenuates the post-stroke brain damage.

In this study, MMP-12 expression was predominantly upregulated (~763-fold vs sham) in mouse ischaemic brains. The post-stroke induction of MMP-12 in mice is consistent with our earlier findings in rats, wherein we reported a predominant upregulation of MMP-12 (~47-fold vs sham at 1-day reperfusion and ~265-fold vs sham at 7-day reperfusion) over other MMPs. MMP-12 can activate other MMPs such as pro-MMP-2 and pro-MMP-3, which, in turn, can activate pro-MMP-1 and pro-MMP-9. Our recent reports clearly demonstrated the detrimental role of the induced MMP-12 on post-stroke brain damage. Further, the mesenchymal stem cell treatment that prevented the post-stroke induction of MMP-12 attenuated the post-stroke brain damage.

Post-stroke induction of MMP-8 (~279-fold vs sham) was the largest after MMP-12 in mice. Our results are in agreement with a recent report wherein the authors...
have demonstrated the upregulation of MMP-8 mRNA and protein in mouse ischaemic brains at 1-day reperfusion subsequent to a transient focal cerebral ischaemia. Elevated MMP-8 brain mRNA expression was also recently reported at 3 and 7 days post-ischaemia induction in a photothrombotic ischaemic mouse model. Although the post-stroke induction of MMP-8 at 1 day after reperfusion in rats is minimal (~3-fold vs sham), the increase in mRNA expression is prominent (~35-fold vs sham at 5 and 7 days of reperfusion) at later reperfusion time points. Overall, the post-stroke induction of MMP-8 was evident in both the rodent stroke models. Post-stroke induction of MMP-8 was also reported in human brain.

Inactivation of MMP-8 either by administration of MMP-8 inhibitor or MMP-8 specific shRNA immediately after reperfusion subsequent to a transient focal cerebral ischaemia reduced the extent of brain damage.

At 1-day reperfusion after a transient focal cerebral ischaemia, MMP-3 was downregulated (~5-fold vs sham) in the ischaemic brains of mice. In contrast, in rats, mRNA expression was upregulated (~11-fold vs sham) along with protein expression at 1-day reperfusion; however no change was noticed in mRNA expression at 3, 5, and 7 days of reperfusion. In addition, increased protein expression of MMP-3 was reported in reactive astrocytes and/or microglia/macrophages at 3 days of reperfusion in mice. Increased MMP-3 protein expression was recently reported in brain tissue of deceased patients who had an ischaemic stroke within the previous 4 days. MMP-3 can proteolytically activate MMP-9. The post-stroke induction of MMP-3 could be detrimental because its inhibition either by administration of its inhibitor or MMP-3 specific shRNA in rats significantly improved the functional outcome of hyperglycaemic stroke.

Upregulation of MMP-2 was reported in the ischaemic brain of rats at 5 days of reperfusion as compared with its expression at the initial time points after reperfusion. In agreement with these findings, we reported a marked increase in MMP-2 activity in rats at 7 days of reperfusion. However, we did not notice a prominent difference in the mRNA expression of MMP-2 until 7 days of reperfusion. In contrast, in this study, MMP-2 was reasonably upregulated (~11-fold vs sham) in mice at 1-day reperfusion. Elevated MMP-2 brain mRNA expression was also recently reported at 3 and 7 days post-ischaemia induction in a photothrombotic ischaemic mouse model. Interestingly, MMP-1a, MMP-10, MMP-15, MMP-16, MMP-17 and MMP-21 were downregulated (>10-fold vs sham) in mice in this study in contrast to rats at 1-day reperfusion. Of all the MMPs that were downregulated in mice, the degree of reduction in MMP-10 mRNA expression (~247-fold vs sham) is predominant over other MMPs. In a thromboembolic stroke model, MMP-10 knockout mice had similar infarct size as the wild-type mice. Administration of MMP-10 to wild-type mice reduced the infarct size. In the same thromboembolic stroke model, administration of MMP-10 in combination with tissue-type plasminogen activator (tPA) significantly reduced the infarct size as compared with tPA alone. In contrast to animal studies, increased MMP-10 protein levels were reported in human ischaemic brain. Most of the studies we discussed here in mice with genetic deletion of certain MMPs are in conventional knockout models (constitutive). The constitutive knockout of a target MMP is likely to result in the compensatory changes in these mice with altered expression of other MMPs. This further complicates the interpretation of the data that will be generated from these animal models. In this study, genetic deletion of MMP-12 prevented the post-stroke upregulation of MMP-12, MMP-2 and MMP-8 and downregulation of MMP-1a, MMP-10 and MMP-21, as well as upregulated MMP-28 as compared with wild-type mice. In fact, the genetic deletion of MMP-12 under normal conditions also resulted in the altered expression...
of several other MMPs. Our findings demonstrated that the MMP-12 knockout mice are not the suitable models to conclusively assess the role of MMP-12. It also raise the question of whether the same apply to other MMP deleted constitutive knockout mice.

In summary, our results demonstrate the differences in the post-stroke expression of MMPs in the ischaemic brain. Of all the MMPs, MMP-12 upregulation is predominant in the ischaemic brain of both rodent species. Because of the compensatory changes, constitutive MMP knockout mice may not be the suitable models for confirmatory studies.

Acknowledgements  We thank Mary Allyson Finger for assistance in manuscript format and review.

Contributors  KKV was involved in the conception and hypotheses delineation, design and execution of the study, analysis and interpretation of results. KRN was involved in animal handling, postsurgical animal care, collection of tissues, conduct of PCR analysis, acquisition and quantification of the data, statistical analysis and manuscript preparation. BC induced ischaemia in animals. IBM and DNF assisted KRN in PCR analysis. AM and IV assisted KRN in agarose gel electrophoresis. JDK, DMP, KMB and KK reviewed and edited the manuscript.

Funding  This work was supported by the Illinois Neurological Institute, OSF HealthCare Foundation.

Competing interests  None declared.

Patient consent  Not required.

Ethics approval  The Institutional Animal Care and Use Committee of the University of Illinois College of Medicine at Peoria.

Provenance and peer review  Commissioned by the CSA; externally peer reviewed.

Data sharing statement  The authors agree to provide upon request the unpublished data that include raw data, metadata and statistical analysis results for the purposes of reproducing the results.

Open access  This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

1. Lee HS, Namkoong K, Kim DH, et al. Hydrogen peroxide-induced alterations of tight junction proteins in bovine brain microvascular endothelial cells. Microvasc Res 2004;68:231–8.
2. Si-Tayeb K, Monvoisin A, Mazzocco C, et al. Matrix metalloproteinase 3 is present in the cell nucleus and is involved in apoptosis. Am J Pathol 2006;169:1390–401.
3. Rosenberg GA, Yang Y. Vasogetic edema due to tight junction disruption by matrix metalloproteinases in cerebral ischemia. Neurosurg Focus 2007;22:e1–9.
4. Wasserman JM, Schlachter LC. Minocycline protects the blood–brain barrier and reduces edema following intracerebral hemorrhage in the rat. Exp Neurol 2007;207:227–37.
5. Yang Y, Candelario-Jalil E, Thompson JF, et al. Increased intranuclear matrix metalloproteinase activity in neurons interferes with oxidative DNA repair in focal cerebral ischemia. J Neurochem 2010;112:134–49.
6. Chelluboina B, Klopfenstein JD, Pinson DM, et al. Matrix metalloproteinase-12 induces blood–brain barrier damage after focal cerebral ischemia. Stroke 2015;46:3523–31.
7. Zhao BQ, Wang S, Kim HY, et al. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med 2006;12:441–5.
8. Cuadrado E, Rosell A, Penalba A, et al. Vascular MMP-9/TIMP-2 and neuronal MMP-10 up-regulation in human brain after stroke: a combined laser microdissection and protein array study. J Proteome Res 2009;8:3191–7.
9. Orbe J, Barrenetxe J, Rodriguez JA, et al. Matrix metalloproteinase-10 effectively reduces infarct size in experimental stroke by enhancing fibrinolysis via a thrombin-activatable fibrinolysis inhibitor-mediated mechanism. Circulation 2011;124:2909–18.
10. Chelluboina B, Warhekar A, Dillard M, et al. Post-transcriptional inactivation of matrix metalloproteinase-12 after focal cerebral ischemia attenuates brain damage. Sci Rep 2015;5:9504.
11. Hafez S, Abdelmajeed M, El-Shafey S, et al. Matrix metalloproteinase 3 exacerbates hemorrhagic transformation and worsens functional outcomes in hyperglycemic stroke. Stroke 2016;47:843–51.
12. Han JE, Lee EJ, Moon E, et al. Matrix Metalloproteinase-8 is a Novel Pathogenetic Factor in Focal Cerebral Ischemia. Mol Neurobiol 2016;53:231–9.
13. Ma F, Martinez-San Segundo P, Barceló V, et al. Matrix metalloproteinase-13 participates in neuroprotection and neurorepair after cerebral ischemia in mice. Neurobiol Dis 2016;91:236–46.
14. Roncal C, Martinez de Lizarrondo A, Salicio A, et al. New thrombolytic strategy providing neuroprotection in experimental ischemic stroke: MMP10 alone or in combination with tissue-type plasminogen activator. Cardiovasc Res 2017;113:1219–29.
15. Hirono J, Sanaki H, Kitada K, et al. Expression of tissue inhibitor of metalloproteinases and matrix metalloproteinases in the ischemic brain of photothermobiology model mice. Neuropathology 2018;29:174–180.
16. Chaturvedi M, Kaczmarek L. MMP-9 inhibition: a therapeutic strategy in ischemic stroke. Mol Neurobiol 2014;49:563–73.
17. Heo JH, Lucero J, Abumya J, et al. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab 1999;19:624–33.
18. Clark AW, Krekoski CA, Bou SS, et al. Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurol Res 1997;19:33–6.
19. Rosell A, Ortega-Aznar A, Alvarez-Sabin J, et al. Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke 2006;37:1399–406.
20. Wang X, Jung J, Asahi M, et al. Effects of matrix metalloproteinase-9 gene knock-out on morphological and motor outcomes after traumatic brain injury. J Neurosci 2000:20:7037–42.
21. Asahi M, Wang X, Mori T, et al. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood–brain barrier and white matter components after cerebral ischemia. J Neurosci 2001;21:7724–32.
22. Svedin P, Hagberg H, Sävman K, et al. Matrix metalloproteinase-9 gene knock-out protects the immature brain after cerebral hypoxia–ischemia. J Neurosci 2007;27:1511–8.
23. Matsumoto S, Kobayashi T, Katoda M, et al. Expression and localization of matrix metalloproteinase-12 in the aorta of cholesterol-fed rabbits: relationship to lesion development. Am J Pathol 1998;153:109–19.
24. Chelluboina B, Klopfenstein JD, Pinson DM, et al. Stem cell treatment after cerebral ischemia regulates the gene expression of apoptotic molecules. Neurochem Res 2014;39:1111–21.
25. Chelluboina B, Nalamolu KR, Mendez GG, et al. Mesenchymal stem cell treatment prevents post-stroke dysregulation of matrix metalloproteinases and tissue inhibitors of metalloproteinases. Cell Physiol Biochem 2017;44:1360–9.
26. Yang Y, Jalal FY, Thompson JF, et al. Tissue inhibitor of metalloproteinases-3 mediates the death of immature oligodendrocytes via TNF-α/TACE in focal cerebral ischemia in mice. J Neuroinflammation 2011;8:108.
27. Candelario-Jalil E, Yang Y, Rosenberg GA. Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience 2009;158:983–94.
28. Yang Y, Hill JW, Rosenberg GA. Multiple roles of metalloproteinases in neurological disorders. Prog Mol Biol Transl Sci 2011;99:241–63.
29. Rosenberg GA, Estrada EY, Dencoff JE. Matrix metalloproteinases and TIMPs are associated with blood–brain barrier opening after reperfusion in rat brain. Stroke 1998;29:2189–95.